

Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study

Bernd Schulte,^{1,a} Christiane S. Schmidt,^{1,a} Jakob Manthey,^{1,2} Lisa Strada,¹ Stefan Christensen,^{3,4} Konrad Cimander,⁵ Herbert Görne,⁶ Pavel Khaykin,⁷ Norbert Scherbaum,⁸ Stefan Walcher,⁹ Stefan Mauss,¹⁰ Ingo Schäfer,¹ Uwe Verthein,¹ Jürgen Rehm,^{2,11-15,✉} and Jens Reimer^{1,16}

¹Centre for Interdisciplinary Addiction Research, Department of Psychiatry, Medical Centre Hamburg-Eppendorf, Hamburg, Germany, ²Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies, Technische Universität Dresden, Dresden, Germany, ³Center for Interdisciplinary Medicine Infectious Diseases, Muenster, Germany, ⁴Department of Gastroenterology and Hepatology, Muenster University Hospital, Muenster, Germany, ⁵Kompetenzzentrum Suchtmedizin, Infektiologie und Cannabis-Therapie, Hannover, Germany, ⁶MediZentrum Hamburg, Praxis für Suchtmedizin, Hamburg, Germany, ⁷Praxis MainFachArzt, Frankfurt am Main, Germany, ⁸LVR-Hospital Essen, Department of Addictive Behaviour and Addiction Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany, ⁹Schwerpunktpraxis Concept, Munich, Germany, ¹⁰Center for HIV and Hepatogastroenterology, Düsseldorf, Germany, ¹¹Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada, ¹²Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada, ¹³Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada, ¹⁴Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada, ¹⁵Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation, and ¹⁶Gesundheit Nord, Bremen, Germany

Background. Patient-reported outcomes (PROs) can help to reduce uncertainties about hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) among people who inject drugs and increase treatment uptake in this high-risk group. Besides clinical data, this study analyzed for the first time PROs in a real-world sample of patients on opioid agonist treatment (OAT) and HCV treatment with DAAs.

Methods. HCV treatment data including virological response, adherence, safety, and PROs of 328 German patients on OAT were analyzed in a pragmatic prospective cohort study conducted from 2016 to 2018. Clinical effectiveness was defined as sustained virological response (SVR) at week 12 after end of treatment and calculated in per-protocol (PP) and intention-to-treat (ITT) analyses. Changes over time in PROs on health-related quality of life, physical and mental health, functioning, medication tolerability, fatigue, concentration, and memory were analyzed by repeated-measures analyses of variances (ANOVAs).

Results. We found high adherence and treatment completion rates, a low number of mainly mild adverse events, and high SVR rates (PP: 97.5% [n = 285]; ITT: 84.5% [n = 328]). Missing SVR data in the ITT sample were mainly caused by patients lost to follow-up after treatment completion. Most PROs showed statistically significant but modest improvements over time, with more pronounced improvements in highly impaired patients.

Conclusions. This real-world study confirms that DAA treatment among OAT patients is feasible, safe, and effective. PROs show that all patients, but particularly those with higher somatic, mental, and social burden, benefit from DAA treatment.

Keywords. direct-acting antivirals; hepatitis C virus; opioid substitution treatment; patient-reported outcome measures.

Injection drug use is a major risk factor for hepatitis C virus (HCV) infection. In most countries, more than half of the people who inject drugs (PWID) are HCV antibody positive

[1], and similar rates are reported among patients on opioid agonist treatment (OAT) [2, 3]. As most of the HCV-related burden results from chronic hepatitis C infections (CHCs) [3], the treatment of OAT patients with CHC is of utmost relevance.

There are excellent therapeutic opportunities within the setting of OAT, as the frequent treatment provider–patient contact allows for continuous monitoring and sustainable HCV management [4]. HCV treatment with direct-acting antivirals (DAAs) among OAT patients is not only feasible and safe, but also results in sustained virological response (SVR) rates comparable to those of non-PWID populations [5–8]. Despite the proven virological effectiveness, HCV treatment uptake among OAT patients is still limited [2, 9]. Besides provider-level barriers [10], patient-related barriers include fear of invasive

Received 8 April 2020; editorial decision 20 July 2020; accepted 7 August 2020.

^aEqual contribution

Correspondence: B. Schulte, PhD, Centre for Interdisciplinary Addiction Research (ZIS), Hamburg University, Medical Center Hamburg Eppendorf (UKE), Department of Psychiatry (W37), Martinistraße 52, 20246 Hamburg (b.schulte@uke.de).

Open Forum Infectious Diseases®

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofaa317

medical interventions and concerns with regard to DAA side effects [11–13].

Beyond virological response, patient-reported outcomes (PROs) provide important information on overall health, symptoms, burden of disease, and response to treatment and are an important tool to improve patient-centered care, as they are free from third-party interpretation [14]. Thus, more than virological effectiveness alone, improvements in PROs may help to reduce patients' fears and increase HCV treatment uptake in OAT settings and beyond [10, 15].

Clinical trials and cohort studies [16–18] have shown improved PROs like health-related quality of life, functioning, work productivity, fatigue, depression, and activity among non-PWID populations on DAA treatment. For OAT patients, comparable data are only available from a post hoc analysis of data collected from phase 3 clinical trials [19], and due to their strict inclusion criteria, the findings might be of limited generalizability. Given this, more real-world data are needed to inform patients and providers on PROs among PWID treated with DAA [20, 21]. The aim of the “Interferon-Free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid Substituted Patients” (INFO) study was to assess the real-world effectiveness, safety, and PROs of DAA treatment among OAT patients in Germany.

METHODS

Study Design and Population

HCV treatment data of OAT patients were collected in a prospective cohort study under clinical routine conditions. Inclusion criteria comprised minimum age of 18 years, opioid dependence according to ICD-10, OAT for at least 3 months, CHC infection with virus genotypes 1–6, eligibility for DAA treatment according to the respective summary of product (SmPC), and written informed consent (Figure 1). Both HCV treatment-naïve and -experienced patients were eligible. Patients with severely impaired cognitive functioning impeding study participation were excluded. Overall, 328 OAT patients from 19 OAT units (on average 17.3 patients per unit, ranging from 3 to 40) spread across 8 out of 16 German federal states participated. Patient recruitment took place between January 2016 and December 2017, and data collection was finished in October 2018 (last follow-up assessment).

Clinical and Patient-Reported Outcome Measures

Clinical effectiveness was defined as a sustained virological response (SVR) at week 12 or week 24 after the end of treatment (SVR_{12/24}). Safety end points were all adverse events (AEs) collected between treatment initiation and week 12 after the end of treatment (t_{SVR12}). An AE was defined as any new untoward




Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the INFO study. Abbreviations: CHC, chronic hepatitis C virus infection; DAA, direct-acting antivirals; GT, genotype; ITT, intention to treat (all patients with first dose); MSCL, Mini Symptom Checklist; OST, opioid substitution treatment; OTI-HSS, Opiate Treatment Index Health Symptom Scale; PP, per protocol (only patients with complete data for SVR12 or SVR24); SmPC, summary of product; SVR12/24, sustained virological response at week 12/24 after treatment.

medical occurrence or worsening of a preexisting medical condition of a patient. Clinicians were asked to rate AEs for their intensity (low, medium, high) and for their assumed relationship with the antiviral medication using the categories “no causal relationship,” “unlikely,” “possible,” “probable,” and “certain.” Clinicians provided categorical ratings on medication adherence and tolerability at week 4 (t_4) and at the end of treatment (t_{EoT}). Moreover, clinicians rated patients’ functioning and illness severity using the Global Assessment of Functioning (GAF) scale [22] and the Clinical Global Impression scales (CGI-S and CGI-I) [23].

Patient-reported outcomes were collected before (t_0), at week 4 (t_4), at the end (t_{EoT}), and 12 and 24 weeks after the end of DAA treatment (t_{svr12} , t_{svr24}). The 12-item Short Form Health Survey (SF-12) [24] was used to measure health-related quality of life on 2 T-standardized composite scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). We used the German version [25], and we imputed up to 2 missing items per person with the respective mean sample weights, using the method described in Perneger et al. [26]. The Mini Symptom Checklist (MSCL) [27] is the most recent German version of the 18-item Brief Symptom Inventory (BSI-18), contains 3 subscores (depression, anxiety, somatization) and a Global Severity Index (GSI), and is T-standardized on a recent German norm sample. The Opiate Treatment Index Health Symptom Scale (OTI-HSS) is a measure of physical health, comprising a checklist of 50 symptoms that opioid users often experience [28]. At t_4 , patients were asked to provide feedback on medication tolerability on the basis of a 4-point Likert scale from “very good” to “poor.” At t_4 and t_{EoT} , patients gave a 5-item assessment on therapy side effects using 4-point scales (1 = agree, 2 = rather agree, 3 = rather disagree, 4 = disagree) (Table 2). In addition, treatment-experienced patients were asked at baseline to retrospectively assess their previous treatment (Supplementary Table 1). To measure fatigue, concentration, and memory, we self-constructed a 12-item questionnaire (Supplementary Table 2), as preexisting instruments were either too long or did not cover all 3 concepts. Patients were asked to fill in the questionnaires at every time point (t_0 – t_{svr24}), except for treatment-related questions on side effects and medication tolerability, which were only asked at t_4 and t_{EoT} .

Patient Consent Statement

The study was conducted in accordance with Good Clinical Practice (GCP), as defined by the International Conference on Harmonisation. For each patient, a written consent was obtained. The design of the work was approved by the Ethics Committee of the Medical Association of Hamburg (reference number PV4603). Secondary ethical votes were approved by local ethical committees in other federal states. The study was registered at clinicaltrials.gov (NCT02969668).

Statistical Analyses

Baseline sample characteristics and safety data were analyzed descriptively. For SVR rates, 95% confidence intervals were calculated. All patients with a first dose of DAA were included in the intention-to-treat (ITT) analysis, whereas the per-protocol (PP) sample comprised only patients with complete data for SVR_{12/24} ($n = 285$). PRO and clinician ratings were first analyzed descriptively using the valid samples at each measurement point from baseline until t_{svr24} , and second, they were tested for significant changes over time with repeated-measures analyses of variances (ANOVAs). In addition, we assessed group \times time interactions on health-related quality of life (SF-12) by comparing patients with low baseline levels (PCS/ MCS < 40) with the remaining sample. For the self-constructed items on fatigue, concentration, and memory, we performed exploratory factor analyses (Varimax rotation) to decide on the number of (sub)scales, and we determined the internal consistencies (Cronbach’s alpha) of the final scales. Among treatment-experienced patients, we compared ratings on treatment tolerability for the previous and the current treatment with dependent-sample t tests. All analyses were performed with IBM SPSS statistics, version 22.

RESULTS

Baseline Sample Characteristics

The 328 OAT patients had a mean age of 44.5 (range: 26–69) years, were predominately male (77.4%), and had been infected with HCV for about 13 years on average (Table 1). Around 80% were treatment-naïve, 18.6% had previously been treated with interferon-based protocols (Table 1). Around two-thirds of the patients were treated with (levo-)methadone, and, according to the last 2 urine tests, around a third were actively using illicit drugs (Table 1).

Global functioning scores (GAF) at baseline indicate a high heterogeneity of the sample. Around two-thirds of the patients fell into the medium categories “moderate/mild/slight impairment,” 17.5% were rated as “serious impairment” or worse, and a similar proportion (17.8%) showed “good” or “superior” functioning (Table 1).

Virological Response

Most patients were treated with a sofosbuvir-based protocol, mostly for 12 weeks (Table 1). Seven patients (2.1%) dropped out before week 4, 9 patients (2.7%) were lost before t_{EoT} , and 27 patients (8.2%) left the study after EoT. Moreover, there were 21 subjects (6.4%) with partially missing RNA test data who finished the study. A number of 274 patients with SVR₁₂ data plus another 11 patients with missing SVR₁₂ but valid SVR₂₄ data resulted in a sample of 285 patients for the primary outcome measure, SVR_{12/24}. Seven out of 285 patients had no SVR, which is an SVR_{12/24} rate of 97.5% (95% CI 95.0%–99.0%) in the PP sample ($n = 285$) (Figure 2). For the ITT sample ($n = 328$),

Table 1. Sociodemographic and Clinical Characteristics of the Patient Sample at Baseline (n = 328)

	% or Mean (SD), Range
Male (n = 328)	77.4
Age (n = 328)	44.5 (8.4), 26–69
Having children (n = 291)	47.4
Living together with children (n = 321)	10.3
Relationship (n = 280)	
Single	60.7
Relationship, not living together	11.8
Relationship, living together	27.5
Employment (n = 324)	
Employed (regular full- or part-time)	20.4
Unemployed/disability pension	67.6
Occasional/other	12.0
Living situation (n = 324)	
Own flat/with partner	65.4
Institutional	19.8
With relatives/friends	8.6
Other/temporary accomodation	5.6
Homeless	0.6
Caucasian ethnicity (n = 322)	98.8
German citizenship (n = 320)	86.6
Migration background (n = 255)	23.2
German language skills (n = 327)	
Very good/native speaker	85.6
Good	11.0
Poor	3.4
Duration of OAT with their current physician (n = 289), y	4.2 (4.6), 0–23
Overall duration of OAT (n = 311), y	11.3 (7.3), 0–35
Substitution medication (n = 325)	
D-/L-methadone (liquid or tablets)	67.7
Buprenorphine (with or without naloxone)	20.0
Other (eg, slow-release morphine, diamorphine)	12.4
(Estimated) duration of HCV infection (n = 309), y	13.7 (7.6), 1–38
Liver cirrhosis (n = 328)	
Cirrhosis, decompensated	2.7
Cirrhosis, compensated	11.0
Cirrhosis, not specified	2.7
No cirrhosis	75.0
Unclear	8.5
Liver fibrosis (n = 328)	
Metavir score F4/cirrhosis	16.5
Metavir score F1–F3	23.5
No fibrosis	11.6
Unclear	48.5
HCV genotype (n = 327)	
1	49.8
2	2.4
3	42.5
4	5.2
HIV status (n = 328)	
Positive	4.0
Negative	83.8
Unknown	12.2
Previously treated for HCV (n = 328)	
Never treated	79.9
Interferon-based	18.6

Table 1. Continued

	% or Mean (SD), Range
Interferon-free	0.6
Unclear	0.9
Antiviral medication (n = 328)	
Sofosbuvir & velpatasvir	41.5
Sofosbuvir & ledipasvir	29.3
Glecaprevir & pibrentasvir	12.2
Elbasvir & grazoprevir	10.1
Ombitasvir, paritaprevir, ritonavir, & dasabuvir	4.6
Other	2.4
Treatment duration (planned; n = 326)	
8 wk	27.0
12 wk	70.6
>12 wk	2.4
Treatment duration (weeks between t0 and EoT; n = 311)	
Up to 10 wk	22.8
>10–14 wk	62.1
>14–18 wk	10.3
>18 wk	4.8
Past 2 urine samples: ≥1 positive sample	
Cocaine (n = 287)	16.4
Benzodiazepines (n = 285)	30.2
Opiates (n = 287)	34.8
Amphetamines (n = 245)	0.8
Global Assessment of Functioning score (n = 326)	
≤30 (unable to function in almost all areas)	1.5
31–40 (major impairment in several areas)	6.1
41–50 (serious impairment)	9.8
51–60 (moderate impairment)	21.8
61–70 (mild impairment)	21.8
71–80 (only slight impairment)	21.2
81–90 (good functioning)	11.7
91–100 (superior functioning)	6.1

Percentages are based on valid numbers, which are indicated in parentheses. Active drug use: ≥1 positive urine samples in the past 12 weeks.

Abbreviations: HCV, hepatitis C virus; OAT, opioid agonist treatment.




Figure 2. Sustained virological response rates (SVR12/24). Abbreviations: ITT, intention to treat (all patients with first dose); PP, per protocol (only patients with complete data for SVR12/24).

the assumption of nonresponse for all 43 missing individuals resulted in an SVR_{12/24} rate of 84.8% (95% CI, 80.4%–88.5%) (Figure 2). However, 27 of these 43 missing individuals (62.8%) had completed DAA treatment, and 25 of them were HCV-RNA negative at t_{EoT}. In total, among all HCV-RNA-negative patients at EoT (n = 287), 89.9% remained negative until SVR₁₂, 1.4% (n = 4) did not achieve SVR, and 8.7% (n = 25) dropped out.

Safety

Between baseline and t_{EoT}, 151 AEs from 76 patients (23.2% of the total sample) were documented. The most frequently reported AEs were nausea (19×), headaches (14×), fatigue (13×), sleeping problems (9×), anemia (6×), loss of appetite (5×), diarrhea (5×), and heartburn/gastroesophageal reflux disease (5×). Clinicians provided intensity ratings for 139 of these 151

AEs, resulting in 33 AEs (23.7%) with low, 81 AEs (58.3%) with medium, and 25 AEs (18.0%) with high intensity. A causal relationship with the antiviral medication was assessed for 92 of 151 AEs, resulting in 22.8% “no causal relationship,” 25.0% “unlikely,” 31.5% “possible,” 16.3% “probable,” and 4.3% “certain.” The 19 AEs probably or certainly related to DAA medications were anemia (5×), fatigue (4×), nausea (3×), and loss of appetite (2×).

Between t_{EoT} and t_{SVR12}, another 65 AEs from 31 patients were reported. In total, between baseline and t_{SVR12}, this resulted in 216 AEs from 85 persons. Moreover, 6 SAEs were reported between baseline and t_{SVR12}, among them 3 deaths (due to drug overdose, suicide, aneurysm), suicidal thoughts, 1 hospitalization, and 1 pregnancy. No causal relationship between all SAEs and the antiviral treatment was reported.

Table 2. Course of HCV Therapy, Patient- and Clinician-Reported Outcomes—Total Sample

Clinician-Reported	T0	T4	EoT	SVR12	SVR24
Medication adherence (n = 301–288), %	—	Very good: 90.4 Good: 9.0 Fair: 0.7	Very good: 86.5 Good: 13.2 Fair: 0.3	—	—
CGI-S (n = 324–256)	3.06 (1.52)	2.95 (1.52)	2.91 (1.50)	2.82 (1.51)	2.80 (1.49)
CGI-I (n = 280–224)	—	3.76 (0.64)	3.65 (0.71)	3.51 (0.75)	3.46 (0.78)
GAF	66.34 (17.00)	68.14 (17.36)	70.27 (17.39)	71.14 (16.66)	71.84 (16.82)
Medication tolerability, clinician-reported (n = 318–305), %	—	Very good: 70.1 Good: 27.0 Moderate: 2.2 Poor: 0.6	Very good: 70.5 Good: 24.6 Moderate: 4.9	—	—
Patient-Reported	T0	T4	EoT	SVR12	SVR24
Medication tolerability, patient-reported (n = 310), %	—	Very good: 53.5 Good: 39.0 Moderate: 7.1 Poor: 0.3	—	—	—
Much bothered by side effects ^a	—	3.54 (0.75)	3.40 (0.90)	—	—
Feeling exhausted and weak ^a	—	2.99 (1.11)	3.03 (1.12)	—	—
Being sad all the time ^a	—	3.47 (0.88)	3.46 (0.90)	—	—
Got done less than I wanted ^a	—	3.01 (1.12)	3.04 (1.14)	—	—
Problems thinking straight ^a	—	3.35 (0.94)	3.32 (0.96)	—	—
SF-12, Physical Component Summary (n = 317–241)	43.66 (9.32)	44.95 (9.14)	45.12 (9.35)	45.44 (9.10)	45.47 (9.05)
SF-12, Mental Component Summary (n = 317–241)	42.35 (11.26)	45.21 (11.14)	45.35 (11.18)	45.73 (11.35)	45.68 (10.93)
MSCL, total score (GSI; n = 327–242)	58.87 (9.32)	56.54 (10.27)	55.96 (11.14)	55.41 (10.72)	55.45 (10.87)
MSCL, subscale somatization (n = 327–242)	57.69 (9.63)	56.56 (9.69)	56.00 (10.22)	54.68 (10.11)	54.94 (10.16)
MSCL, subscale depression (n = 327–242)	58.16 (8.72)	55.61 (9.62)	55.41 (9.84)	55.23 (9.81)	55.38 (9.92)
MSCL, subscale anxiety (n = 327–242)	57.44 (10.95)	55.37 (11.32)	54.89 (11.47)	54.64 (10.80)	54.95 (11.33)
OTI-HSS (n = 326–237)	12.17 (7.62)	11.14 (7.75)	11.14 (8.32)	10.14 (8.06)	10.23 (8.13)
Fatigue, concentration, and memory, total score ^b (n = 325–243)	0.79 (0.71)	0.72 (0.77)	0.68 (0.74)	0.63 (0.68)	0.66 (0.73)
Fatigue, concentration, and memory, subscale fatigue ^b (n = 325–243)	0.93 (0.89)	0.85 (0.94)	0.80 (0.96)	0.70 (0.82)	0.72 (0.87)
Fatigue, concentration, and memory, subscale concentration and memory ^b (n = 325–243)	0.69 (0.71)	0.62 (0.75)	0.60 (0.71)	0.58 (0.66)	0.62 (0.70)

Data are presented as means and standard deviations or %. Categories of clinician-rated medication adherence: “very good” (100% of the medication taken), “good” (at least 90%), “fair” (at least 80%), “poor” (<80%).

Abbreviations: CGI-I, Clinical Global Impression–improvement (ranging from 1 = “very much improved” to 7 = “very much worsened”); CGI-S, Clinical Global Impression–severity (ranging from 1 = “not at all ill” to 7 = “extremely ill”); GAF = Global Assessment of Functioning (0–100; higher scores indicate better functioning); GSI, Global Severity Index; HCV, hepatitis C virus; MCS, Mental Component Summary; MSCL, Mini Symptom Checklist, with GSI (higher scores indicate worse mental health); OTI-HSS, Opiate Treatment Index–health symptoms scale (higher scores indicate worse physical health); PCS, Physical Component Summary; SF-12, Short Form Health Assessment, consisting of PCS and MCS (higher scores indicate better quality of life).

^a“Altogether, how do/did you feel during HCV treatment?” Response options: 1 = agree, 2 = rather agree, 3 = rather disagree, 4 = disagree (n = 310–287).

^bHigher scores indicate higher impairments, ranging from 0 = “not at all” to 4 = “very much.”

Adherence and Tolerability (Patient- and Clinician-Reported)

Medication adherence ($n = 288$) at t_{EoT} was mainly rated as “very good”; that is, patients reported having taken all of the medication (Table 2). Around 90% of both patients and clinicians stated that medication tolerability was either “good” or “very good” (Table 2). The high tolerability ratings are supported by the results of the 5 additional items on therapy side effects and depression, with mean values between 3 (rather disagree) and 4 (disagree) (Table 2). In comparison with previous HCV treatments (94% interferon-based), treatment-experienced patients reported substantially reduced side effects while on the current DAA treatment (Supplementary Table 2).

Physical and Mental Health Outcomes

Health-related quality of life, as measured with the SF-12, was clearly reduced compared with the general population [24, 25], who have mean values (SD) of approximately 50 (10). In our sample, baseline mean PCS (SD) was 43.7 (9.3), and the mean MCS (SD) was 42.4 (11.3). During the course of treatment, MCS showed small but significant improvement (Tables 2 and 3) persisting after treatment, whereas PCS did not change over time. Patients with clearly reduced health-related quality of life at baseline (PCS or MCS < 40) showed a considerable level of improvement, mainly between baseline and t_4 (Figure 3).

In the Mini-SCL (MSCL), the Global Severity Index (GSI) for the total sample at baseline (SD) was 58.87 (9.32), which indicates, compared with the population mean (SD) of 50 (10), a clearly increased symptom load ($t(326) = 17.21; P < .001$), consistent over all subscales: somatization, depression, and anxiety (Table 2). In the course of the DAA treatment, all MSCL scores modestly improved, mainly between baseline and t_4 (Tables 2 and 3). Patients with higher psychological distress at baseline showed higher improvements over time.

According to OTI-HSS at baseline, patients reported, on average (SD), 12.17 (7.62) physical health symptoms. Similar to other PROs, there were modest improvements over time (Tables 2 and 3); these improvements were more prominent in patients with higher symptom loads at baseline.

The self-constructed 12 items on fatigue, concentration, and memory were divided into 2 subscales: 1 subscale for fatigue and 1 subscale for concentration and memory, as supported by exploratory factor analyses (Supplementary Table 1). Mean values include all patients with no more than 1 missing value per subscale or 2 missing values in total. At baseline, the mean of the total scale “fatigue, concentration, and memory” (SD) was 0.79 (0.71), indicating a mean impairment between 0 (not at all) and 1 (a little) (Table 2); 8.5% of the sample had a minimum value of 0.00, indicating no impairment at all. At the other end of the spectrum, 9.8% had a mean score of 2 or higher, and the maximum value ($n = 1$) was 3.17. Overall, patients scored higher on the fatigue subscale than on the subscale on concentration and memory (Table 2). Over time, fatigue, concentration, and

Table 3. Course of HCV Therapy, Patient- and Clinician-Reported Outcomes—Per-Protocol Sample (n = SVR12)

	Clinician-Reported				Patient-Reported		Time Effect in Repeated-Measures ANOVA		
	T0	T4	EoT	SVR12	T0	T4	EoT	SVR12	
CGI-S (n = 270)	3.02 (1.55)	2.94 (1.53)	2.93 (1.50)	2.83 (1.52)	3.02 (1.55)	2.94 (1.53)	2.93 (1.50)	2.83 (1.52)	F (2.60, 698.68) = 6.03, P = .001
GAF (n = 268)	66.45 (17.49)	68.50 (17.59)	70.15 (17.39)	70.97 (16.72)	66.45 (17.49)	68.50 (17.59)	70.15 (17.39)	70.97 (16.72)	F (2.45, 653.70) = 23.27, P < .001
Patient-Reported									
SVR12, PCS (n = 248)	44.42 (9.44)	45.25 (9.28)	45.25 (9.42)	45.44 (9.20)	44.42 (9.44)	45.25 (9.28)	45.25 (9.42)	45.44 (9.20)	n.s.
SVR12, MCS (n = 248)	43.19 (11.34)	45.62 (10.88)	45.10 (11.44)	45.99 (11.39)	43.19 (11.34)	45.62 (10.88)	45.10 (11.44)	45.99 (11.39)	F (2.85, 704.52) = 7.28, P < .001
MSCL, total score (GSI; n = 262)	58.31 (9.37)	56.16 (10.24)	55.78 (11.13)	55.24 (10.76)	58.31 (9.37)	56.16 (10.24)	55.78 (11.13)	55.24 (10.76)	F (2.78, 725.10) = 15.44, P < .001
MSCL, subscale somatization (n = 262)	57.18 (9.61)	56.20 (9.74)	55.64 (10.09)	54.63 (10.14)	57.18 (9.61)	56.20 (9.74)	55.64 (10.09)	54.63 (10.14)	F (2.84, 741.17) = 8.71, P < .001
MSCL, subscale depression (n = 262)	57.82 (8.74)	55.15 (9.53)	55.16 (10.01)	55.05 (9.83)	57.82 (8.74)	55.15 (9.53)	55.16 (10.01)	55.05 (9.83)	F (2.84, 740.14) = 17.00, P < .001
MSCL, subscale anxiety (n = 262)	56.58 (11.01)	54.81 (11.17)	54.90 (11.47)	54.45 (10.84)	56.58 (11.01)	54.81 (11.17)	54.90 (11.47)	54.45 (10.84)	F (3, 783) = 6.42, P < .001
OTI-HSS (n = 255)	11.57 (7.37)	10.96 (7.71)	10.87 (8.09)	10.13 (8.00)	11.57 (7.37)	10.96 (7.71)	10.87 (8.09)	10.13 (8.00)	F (2.88, 731.00) = 6.00, P = .001
Fatigue, concentration, and memory, total score (n = 261) ^a	0.76 (0.70)	0.68 (0.75)	0.66 (0.75)	0.61 (0.67)	0.76 (0.70)	0.68 (0.75)	0.66 (0.75)	0.61 (0.67)	F (2.86, 743.99) = 6.85, P < .001
Fatigue, concentration, and memory, subscale fatigue (n = 261) ^a	0.88 (0.89)	0.81 (0.93)	0.78 (0.98)	0.69 (0.82)	0.88 (0.89)	0.81 (0.93)	0.78 (0.98)	0.69 (0.82)	F (2.81, 731.28) = 6.35, P < .001
Fatigue, concentration, and memory, subscale concentration and memory (n = 261) ^a	0.67 (0.69)	0.58 (0.73)	0.57 (0.70)	0.56 (0.65)	0.67 (0.69)	0.58 (0.73)	0.57 (0.70)	0.56 (0.65)	F (2.87, 739.69) = 4.74, P = .003

Data are presented as means and standard deviations. Abbreviations: CGI-S, Clinical Global Impression–severity (ranging from 1 = “not at all ill” to 7 = “extremely ill”); GAF, Global Assessment of Functioning (0–100; higher scores indicate better functioning); GSI, Global Severity Index; MCS, Mental Component Summary; MSCL, Mini-Symptom Checklist, with GSI (higher scores indicate worse mental health); OTI-HSS, Opiate Treatment Index–health symptoms scale (higher scores indicate worse physical health); PCS, Physical Component Summary; SF-12, Short Form Health Assessment, consisting of PCS and MCS (higher scores indicate better quality of life).

^aHigher scores indicate higher impairments, ranging from 0 = “not at all” to 4 = “very much.”

memory showed modest improvements (Tables 2 and 3), with higher improvements in patients who had more impairments at baseline.

The clinician-reported severity rating CGI-S had, at baseline, a mean score (SD) of 3.06 (1.52) and showed modest improvement over time.

DISCUSSION

The aim of this prospective cohort study was to analyze the clinical effectiveness, safety, and PROs of DAA treatment among OAT patients under the conditions of clinical routine treatment in Germany.

The first main study outcome was that DAA treatment among OAT patients is feasible, safe, and results in high SVR rates. Feasibility of DAA treatment in OAT settings is confirmed by the high adherence and treatment completion rates in our sample, also in accordance with previous studies [29, 30]. Compared with clinical data from IFN-ribavirin-based treatment among OAT patients [31] and even compared with previous clinical trials on DAA treatment among OAT patients [32], we found a low prevalence of AEs. Between baseline and EoT, around a quarter of patients reported on average 2 mainly mild AEs like nausea, headache, or fatigue, which are deemed reversible after treatment completion [19]. The high adherence and completion rates and the low number of mainly mild AEs went along with high SVR rates (PP, 97.5%; ITT, 84.5%), comparable to those found in previous studies [5, 8], also from Germany [6]. The lower rate in our ITT sample is a consequence of the conservative assumption treating all missing data on SVR like treatment failures. An alternative, probably more realistic assumption considers that more than half of our dropouts (27 out of 43) completed treatment, and 25 of these 27 patients were RNA-negative at EoT. Given that in the total sample virtually all patients who were RNA-negative at EoT did achieve

SVR (98.6%), we have reason to assume SVR in at least 24 of these dropouts. This assumption would result in an SVR_{12/24} rate of 92.1% for the ITT sample.

The second main outcome of this study was that DAA treatment results in improved PROs among OAT patients. In contrast to interferon- and ribavirin-based protocols [31], health-related quality of life does not deteriorate during DAA treatment. Still, compared with the findings of a post hoc analysis of phase 3 clinical trial data on PROs among OAT patients in antiviral treatment [19], the improvements in our study were modest, especially with regard to the PCS of the SF-12. However, as smaller improvements were also found in other real-world populations [33, 34], 1 explanation might be that the exclusion of “difficult-to-treat” patients from registration trials results in better PROs. In our sample, health-related quality of life (PCS and MCS) at baseline was substantially reduced compared with the general population, which is consistent with a recent German large-scale study among OAT patients [35].

Reasons why patients with higher baseline HRQoL impairments reported significant improvements on DAA treatment may be 2-fold. On the one hand, statistical effects need to be considered, such as regression to the mean or ceiling effects among those with very low or very high baseline levels, respectively. On the other hand, CHC is a systemic disease, and a number of metabolic, autoimmune, and neuro-psychiatric extrahepatic manifestations (EHMs) associated with CHC have been described that also affect patients’ health-related quality of life but can be improved or eliminated after successful antiviral treatment [36]. Given this, patients with higher baseline HRQoL impairments might have experienced a stronger increase in HRQoL during and after treatment due to improvements in EHM. In general, the fact that SVR reduces the risk of EHM [37, 38] is another reason why individuals with CHC should be treated, including patients with opioid use disorders.




Figure 3. Estimated marginal means of the Physical Composite Score (PCS) and Mental Composite Score (MCS) means of the 12-item Short-Form Health Survey (SF-12) for patients with valid data for all measurement points between baseline and tSVR12. Groups are divided according to their baseline PCS/MCS levels (<40 vs ≥40 points).

With regard to the other PROs (physical/mental health, fatigue, cognitive impairment), we also found consistent but modest improvements over time, as well as substantial improvements among those with higher impairments. Similar to HRQoL, these findings need to be addressed in further research. The information that especially patients with high self-reported health burden will benefit from PROs on DAA treatment could be relevant for both patients and providers.

Some limitations need to be considered. First of all, as shown in [Table 2](#), no data on the stage of liver disease from more than half of the patients could be obtained, which impeded further analyses on PROs depending on the severity of the liver disease. However, the relevance of the stage of liver disease on HRQoL during DAA treatment might not be as important as presumed. Recent studies show that patients with early and advanced fibrosis have comparable improvements, and other factors like sociodemographic characteristics or psychiatric comorbidities might have a higher impact on HRQoL [35, 39, 40]. Another limitation is that that patient-reported data on fatigue, concentration, and memory need to be carefully interpreted, as they were not assessed with a validated instrument.

CONCLUSIONS

DAA treatment among PWIDs is feasible, safe, and effective. Besides clinical effectiveness, health-related quality of life and other PROs improve during DAA treatment, in particular among those OAT patients with higher somatic, mental, and social burden. These findings may reduce uncertainties about HCV treatment with DAAs in OAT settings in clinical routine treatment, for both patients and providers. Given the high prevalence rates of CHC infections among OAT patients and the excellent therapeutic opportunities in this setting, more investments are needed to improve the linkage to HCV care.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We thank Elke Rühling and Dr. Philipp Hiller for supporting the data processing.

Financial support. This work was supported by Bristol-Myers Squibb GmbH (unrestricted educational grant). Bristol-Myers Squibb GmbH had no role in the design of the study, the collection, analysis, or interpretation of the data, or the writing of the manuscript.

Potential conflicts of interest. Dr. Schulte reports grants and nonfinancial support from Camurus AB, Sweden; personal fees and nonfinancial support from AbbVie GmbH, Germany; outside the submitted work. Dr. Christensen reports personal fees from BMS GmbH, Germany; AbbVie GmbH, Germany; Janssen-Cilag GmbH, Germany; ViiH GmbH, Germany; Gilead GmbH, Germany; and MSD GmbH, Germany; outside the submitted work. Dr. Cimander reports personal fees from BMS GmbH, Germany; AbbVie GmbH, Germany; Camurus GmbH, Germany; Indivior

GmbH, Germany; Gilead GmbH, Germany; MSD GmbH, Germany; Mundipharma GmbH, Germany; Sanofi-Aventis GmbH, Germany; Spectrum Therapeutics; Tilray and Hexal GmbH, Germany; outside the submitted work. Mr Görne and Dr. Khaykin report personal fees from Sanofi-Aventis GmbH, Germany; AbbVie GmbH, Germany; Janssen-Cilag GmbH, Germany; ViiH GmbH, Germany; Gilead GmbH, Germany; and MSD GmbH, Germany; outside the submitted work. Mr. Walcher reports personal fees from Sanofi-Aventis GmbH, Germany; AbbVie GmbH, Germany; Janssen-Cilag GmbH, Germany; ViiH GmbH, Germany; Gilead GmbH, Germany; MSD GmbH, Germany; Camurus GmbH, Germany; Indivior GmbH, Germany; and Hexal GmbH, Germany; outside the submitted work. Dr. Mauss reports personal fees from AbbVie GmbH, Germany; Janssen-Cilag GmbH, Germany; ViiH GmbH, Germany; Gilead GmbH, Germany; MSD GmbH, Germany; and Myr Pharmaceuticals; outside the submitted work. Prof. Scherbaum reports personal fees and nonfinancial support from AbbVie GmbH, Germany; personal fees from Camurus GmbH, Germany; personal fees from Indivior GmbH, Germany; personal fees from Medice; personal fees from MSD GmbH, Germany; personal fees and nonfinancial support from Mundipharma GmbH, Germany; personal fees from Sanofi-Aventis GmbH, Germany; personal fees and nonfinancial support from Janssen-Cilag GmbH, Germany; personal fees and nonfinancial support from Hexal GmbH, Germany; outside the submitted work. Dr. Verthein reports personal fees from Mundipharma GmbH, Germany; grants from Camurus AB, Sweden; nonfinancial support from Camurus GmbH, Germany; outside the submitted work. Prof. Reimer reports grants from BMS GmbH, Germany; during the conduct of the study. Prof. Reimer reports personal fees and nonfinancial support from AbbVie GmbH, Germany; personal fees from BMS GmbH, Germany; MSD GmbH, Germany; Janssen-Cilag GmbH, Germany; and Gilead GmbH, Germany; outside the submitted work. Ms. Schmidt, Dr. Strada, Mr. Manthey, Prof. Rehm, and Prof. Schäfer have nothing to disclose. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* 2017; 5:e1192-207.
- Schulte B, Schmidt CS, Strada L, et al. Hepatitis C virus prevalence and incidence in a large nationwide sample of patients in opioid substitution treatment in Germany: a prospective cohort study. *Clin Infect Dis* 2020; 10:2199-205.
- Meijerink H, White RA, Lovlie A, et al. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030. *BMC Infect Dis* 2017; 17:541.
- Ti L, Socias ME, Wood E, et al. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. *PLoS One* 2018; 13:e0194162.
- Macias J, Morano LE, Tellez F, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. *J Hepatol* 2019; 71:45-51.
- Christensen S, Buggisch P, Mauss S, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? *Addiction* 2018; 113:868-82.
- Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. *Int J Drug Policy* 2018; 62:74-7.
- Graf C, Mucke MM, Dultz G, et al. Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis. *Clin Infect Dis* 2020; 70(11):2355-65.
- Midgard H, Bramness JG, Skurtveit S, et al. Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study. *PLoS One* 2016; 11:e0166451.
- Grebely J, Drolet M, Nwankwo C, et al. Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: the C-SCOPE study. *Int J Drug Policy* 2019; 63:29-38.

11. Crowley D, Cullen W, Laird E, et al. Exploring patient characteristics and barriers to hepatitis C treatment in patients on opioid substitution treatment attending a community based fibro-scanning clinic. *J Transl Int Med* **2017**; 5:112–9.
12. Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? *PLoS One* **2018**; 13:e0207226.
13. Bryant J, Rance J, Hull P, et al. Making sense of “side effects”: counterpublic health in the era of direct-acting antivirals. *Int J Drug Policy* **2019**; 72:77–83.
14. Bingham CO 3rd, Noonan VK, Auger C, et al. Montreal Accord on Patient-Reported Outcomes (PROs) use series - paper 4: patient-reported outcomes can inform clinical decision making in chronic care. *J Clin Epidemiol* **2017**; 89:136–41.
15. Madden A, Hopwood M, Neale J, Treloar C. Acceptability of patient-reported outcome and experience measures for hepatitis C treatment among people who use drugs. *Patient* **2019**; 12:259–65.
16. Younossi ZM, Stepanova M, Gordon S, et al. Patient-reported outcomes following treatment of chronic hepatitis C virus infection with sofosbuvir and velpatasvir, with or without voxilaprevir. *Clin Gastroenterol Hepatol* **2018**; 16:567–74.e6.
17. Kracht PAM, Lieveld FI, Amelung LM, et al. The impact of hepatitis C virus direct-acting antivirals on patient-reported outcomes: a Dutch prospective cohort study. *Infect Dis Ther* **2018**; 7:373–85.
18. Evon DM, Sarkar S, Amador J, et al. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: the PROP UP study. *J Hepatol* **2019**; 71:486–97.
19. Stepanova M, Thompson A, Doyle J, et al. Hepatitis C virus-infected patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. *J Infect Dis* **2018**; 217:1033–43.
20. Marcellin F, Roux P, Protopopescu C, et al. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. *Expert Rev Gastroenterol Hepatol* **2017**; 11:259–68.
21. Mahajan R. Real world data: additional source for making clinical decisions. *J Appl Basic Med Res* **2015**; 5:82.
22. Bell CC. DSM-IV: diagnostic and statistical manual of mental disorders. *JAMA* **1994**; 272:828–9.
23. Guy W. *The Clinical Global Impression Scale. The ECDEU Assessment Manual for Psychopharmacology Revised*. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; **1976**.
24. Ware J Jr, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* **1996**; 34:220–33.
25. Morfeld M, Kirchberger I, Bullinger M. *SF-36 Fragebogen zum Gesundheitszustand: Deutsche Version des Short Form-36 Health Survey*. Göttingen: Hogrefe; **2011**.
26. Perneger TV, Burnand B. A simple imputation algorithm reduced missing data in SF-12 health surveys. *J Clin Epidemiol* **2005**; 58:142–9.
27. Franke GH, Jaeger S, Glaesmer H, et al. Psychometric analysis of the Brief Symptom Inventory 18 (BSI-18) in a representative German sample. *BMC Med Res Methodol* **2017**; 17:14.
28. Darke S, Ward J, Zador D, Swift G. A scale for estimating the health status of opioid users. *Br J Addict* **1991**; 86:1317–22.
29. Butner JL, Gupta N, Fabian C, et al. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. *J Subst Abuse Treat* **2017**; 75:49–53.
30. Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. *Clin Infect Dis*. **In press**.
31. Reimer J, Schmidt CS, Schulte B, et al. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. *Clin Infect Dis* **2013**; 57(Suppl 2):S97–104.
32. Grebely J, Feld JJ, Wyles D, et al. Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies. *Open Forum Infect Dis* **2018**; 5:XXX–XX.
33. Saeed S, Moodie EEM, Strumpf E, et al; Canadian Co-Infection Cohort Study Investigators. Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/hepatitis C co-infected individuals. *J Viral Hepat* **2018**; 25:1507–14.
34. Loo N, Lawitz E, Alkhoury N, et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. *World J Gastroenterol* **2019**; 25:2229–39.
35. Strada L, Schmidt CS, Rosenkranz M, et al. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: a cross-sectional study. *Subst Abuse Treat Prev Policy* **2019**; 14:2.
36. Kuna L, Jakab J, Smolic R, et al. HCV extrahepatic manifestations. *J Clin Transl Hepatol* **2019**; 7:172–82.
37. Rossi C, Jeong D, Wong S, et al; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. *J Hepatol* **2019**; 71:1116–25.
38. Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. *Gut* **2018**; 67:553–61.
39. Cossais S, Schwarzingler M, Pol S, et al. Quality of life in patients with chronic hepatitis C infection: severe comorbidities and disease perception matter more than liver-disease stage. *PLoS One* **2019**; 14:e0215596.
40. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. *J Hepatol* **2015**; 63:337–45.